The construction project of anti Xinguan drug production base of the group's Xiansheng pharmaceutical started

Release time:

2022-06-13

The construction project of anti Xinguan drug production base of the group's Xiansheng pharmaceutical started

On the morning of June 8, the construction project of the commercial production base of anti Xinguan drugs of Xiansheng Pharmaceutical Co., Ltd., which was contracted by the group company, held a commencement ceremony in Jiangbei new area, Nanjing. Ma Jinshan, vice president of the group company and head of Nanjing company, attended the event. The base focuses on the planning and production of anti novel coronavirus drugs, which are used for the prevention and treatment of close contact people who have been exposed to the positive test of neocoronavirus, and help the rapid formation of a three-dimensional prevention and control system in China that takes vaccines as prevention and oral administration as treatment, which provides a solid guarantee for the success of anti epidemic. It is an anti epidemic project that the group company participates in again outside the construction of vaccine workshops. The project was approved and filed in early May. At present, the pile foundation construction permit has been obtained, and the "four supplies and one leveling" on site is being promoted at full speed. It is planned to complete the capping of ssd8432 production workshop by the end of October this year, and strive to put into production by the end of the year. (Nanjing company)

Commencement of Qinghai Taifeng lithium battery material project undertaken by the group company

The group has won the qualification for independent evaluation of intermediate professional titles of Construction Engineering Series

Recommended news

2026-10-08

The Group dispatched representatives to attend the Exchange Meeting on Construction Project Quality and Safety Management and the On-site Observation Session.

In late September, the China Construction Enterprise Management Association organized an experience-sharing and on-site observation conference on quality and safety management in construction projects in Guangzhou, which was attended by representatives from the Group.

2026-09-21

Empowering Communities Through Health: Experts Bring Science-Based Education to Qian’an

On September 18, Jiangsu Qian’an Construction Group, in collaboration with the Science Education Base of Qidong People’s Hospital, hosted the 2026 National Science Popularization Event.

2026-09-18

Benchmarking against global standards! The Jotun Zhangjiagang project has successfully passed the safety audit conducted by its Norwegian headquarters.

In mid-September, a foreign‑owned expert audit team from Jotun’s Norwegian headquarters conducted a three‑day, headquarter‑level specialized safety audit on the Jotun Zhangjiagang project site undertaken by the Group.

2026-09-18

The Roche (Shanghai) project of the Group has successfully achieved 2 million safe man-hours.

On September 17, the Roche (Shanghai) Biopharmaceutical Production Base project, undertaken by the Group, successfully reached the milestone of 2 million safe man-hours.

2026-09-18

The Group dispatched personnel to attend the training on building trustworthy quality teams in chemical engineering construction.

On September 16–17, the China Chemical Construction Enterprises Association held a training course on building “Quality‑Trusted Work Teams” in Chengdu, with representatives from the Group in attendance. The session featured a live lecture by Shi Jie, a senior expert of the Association.

2026-09-09

Good News Abounds | The Group Has Secured Multiple Emerging Industry Projects in Succession

In the golden autumn season, bountiful harvests abound, and new‑generation growth sectors showcase their strength. Since August, leveraging its deep-rooted expertise and core competencies in industrial installation, the Group has successively won bids for five key projects in emerging productivity fields, with a total contract value exceeding RMB 250 million, injecting robust momentum into its resilient year‑end performance.